2026-10-11T22:37:11Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33992011 2026-09-25T04:25:29Z category_388 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma.docx Markus Maulhardt (24172110) Alexander Casimir Angleitner (24172341) Judith Büntzel (18209834) Gina Westhofen (25107013) Margarete Elisabeth Laage (25107016) Justin Hasenkamp (8847209) Detlef Thomas Haase (25107019) Hannes Treiber (11842827) Enver Aydilek (25107022) Anna Lena Illert (12541489) Wolfram Jung (14993291) Gerald Georg Wulf (25107028) Oncology and Carcinogenesis not elsewhere classified acute leukemia allo-HCT auto-HCT multiple myeloma secondary malignancies therapy-related hematological malignancies <p>Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allogeneic HCT (allo-HCT). We conducted a retrospective single-center study of adult MM patients who underwent first auto-HCT between 2010 and 2025 and subsequently developed t-HM, analyzing clinical, molecular, cytogenetic features, treatment strategies, and outcomes, with a focus on allo-HCT. Among 519 patients, 23 (4.4%) developed t-HM, including therapy-related acute myeloid leukemia (43%), myelodysplastic syndrome (35%), and B-cell acute lymphoblastic leukemia (17%), with a median latency of 58.7 months after auto-HCT. High-risk genetics were common, including TP53 mutations in 52% and complex cytogenetics in 35%. Fourteen patients (61%) underwent allo-HCT, mainly with reduced-intensity conditioning. Median overall survival (OS) for the cohort was 31.5 months, while patients receiving allo-HCT had significantly superior OS compared with non-transplanted patients (median not reached vs. 2.5 months; P = 0.046). Therapy-related hematologic malignancies after MM treatment are uncommon but aggressive and genetically high-risk. In this cohort, allo-HCT was associated with improved survival and may represent a potentially curative approach in selected patients despite substantial toxicity.</p> 2026-09-25T04:25:29Z Dataset Dataset 10.3389/fonc.2026.1887912.s002 https://figshare.com/articles/dataset/Data_Sheet_1_Allogeneic_hematopoietic_cell_transplantation_for_therapy-related_hematological_malignancies_in_patients_with_multiple_myeloma_docx/33992011 CC BY 4.0